Tumorigenic cells can be redirected to adopt a normal phenotype when transplanted into cleared mammary fat pads of juvenile female mice in specific ratios with normal epithelial cells. The redirected tumorigenic cells enter stem cell niches and provide progeny that differentiate into all mammary epithelial subtypes. We have developed an in vitro model that mimics the in vivo phenomenon. The shift in phenotype to redirection should be accomplished through a return to a normal gene expression state. To measure this shift, we interrogated the transcriptome of various in vitro model states in search for casual genes. For this study, expression of growth factors, cytokines, and their associated receptors was examined. In all, we queried 251 growth factor and cytokine-related genes. We found numerous growth factor and cytokine genes whose expression levels switched from expression levels seen in cancer cells to expression levels observed in normal cells. The comparisons of gene expression between normal mammary epithelial cells, tumor-derived cells, and redirected cancer cells have revealed insight into active and inactive growth factors and cytokines in cancer cell redirection.
Get full access to this article
View all access options for this article.
References
1.
BrunoRD and SmithGH. (2012). Reprogramming non-mammary and cancer cells in the developing mouse mammary gland. Semin Cell Dev Biol, 23:591–598.
2.
BoulangerCA, MackDL, BoothBW and SmithGH. (2007). Interaction with the mammary microenvironment redirects spermatogenic cell fate in vivo. Proc Natl Acad Sci U S A, 104:3871–3876.
3.
BoothBW, MackDL, Androutsellis-TheotokisA, McKayRD, BoulangerCA and SmithGH. (2008). The mammary microenvironment alters the differentiation repertoire of neural stem cells. Proc Natl Acad Sci U S A, 105:14891–14896.
4.
BoulangerCA, BrunoRD, Rosu-MylesM and SmithGH. (2012). The mouse mammary microenvironment redirects mesoderm-derived bone marrow cells to a mammary epithelial progenitor cell fate. Stem Cells Dev, 21:948–954.
5.
BoulangerCA, BrunoRD, MackDL, GonzalesM, CastroNP, SalomonDS and SmithGH. (2013). Embryonic stem cells are redirected to non-tumorigenic epithelial cell fate by interaction with the mammary microenvironment. PloS One, 8:e62019.
6.
BoothBW, BoulangerCA, AndersonLH and SmithGH. (2010). The normal mammary microenvironment suppresses the tumorigenic phenotype of mouse mammary tumor virus-neu-transformed mammary tumor cells. Oncogene, 30:679–689.
7.
BussardKM, BoulangerCA, BoothBW, BrunoRD and SmithGH. (2010). Reprogramming human cancer cells in the mouse mammary gland. Cancer Res, 70:6336–6343.
8.
BussardKM and SmithGH. (2012). Human breast cancer cells are redirected to mammary epithelial cells upon interaction with the regenerating mammary gland microenvironment in-vivo. PloS One, 7:e49221.
9.
RosenfieldSM and SmithGH. (2013). Redirection of human cancer cells upon the interaction with the regenerating mouse mammary gland microenvironment. Cells, 2:43–56.
10.
AraldiRP, ModoloDG, de Sa JuniorPL, ConsonniSR, de CarvalhoRF, RopertoFP, BecakW and de Cassia StoccoR. (2016). Genetics and metabolic deregulation following cancer initiation: a world to explore. Biomed Pharmacother, 82:449–458.
11.
TamWL and WeinbergRA. (2013). The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med, 19:1438–1449.
12.
SchnittSJ. (2010). Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. Mod Pathol, 23 (Suppl. 2): S60–S64.
13.
ParkJP, BlandingWM, FeltraccoJA and BoothBW. (2015). Validation of an in vitro model of erbB2 cancer cell redirection. In Vitro Cell Dev Biol Anim, 51:776–786.
14.
GentlemanRC, CareyVJ, BatesDM, BolstadB, DettlingM, DudoitS, EllisB, GautierL, GeY, et al. (2004). Bioconductor: open software development for computational biology and bioinformatics. Genome Biol, 5:R80.
15.
GautierL, CopeL, BolstadBM and IrizarryRA. (2004). affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 20:307–315.
16.
LawCW, AlhamdooshM, SuS, SmythGK and RitchieME. (2016). RNA-seq analysis is easy as 1-2-3 with limma, Glimma and edgeR. F1000Res, 5:1408.
17.
RitchieME, PhipsonB, WuD, HuY, LawCW, ShiW and SmythGK. (2015). limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res, 43:e47.
18.
CarvalhoBS and IrizarryRA. (2010). A framework for oligonucleotide microarray preprocessing. Bioinformatics, 26:2363–2367.
19.
SmythGK, RitchieM, ThorneN, WettenhallJ, ShiW and HuY. limma: Linear Models for Microarray and RNA-Seq DataUser's Guide. 2016, www.bioconductor.org/packages/release/bioc/vignettes/limma/inst/doc/usersguide.pdf
20.
MedinaD, ObornCJ, KittrellFS and UllrichRL. (1986). Properties of mouse mammary epithelial cell lines characterized by in vivo transplantation and in vitro immunocytochemical methods. J Natl Cancer Inst, 76:1143–1156.
21.
CardiffRD, AnverMR, GustersonBA, HennighausenL, JensenRA, MerinoMJ, RehmW, RussoJ, TavassoliFA, et al. (2000). The mammary pathology of genetically engineered mice: the consensus report and recommendations from the Annapolis meeting. Oncogene, 19:968–988.
22.
TanejaP, FrazierDP, KendigRD, MaglicD, SugiyamaT, KaiF, TanejaNK and InoueK. (2009). MMTV mouse models and the diagnostic values of MMTV-like sequences in human breast cancer. Expert Rev Mol Diagn, 9:423–440.
23.
HardyKM, BoothBW, HendrixMJ, SalomonDS and StrizziL. (2010). ErbB/EGF signaling and EMT in mammary development and breast cancer. J Mammary Gland Biol Neoplasia, 15:191–199.
24.
RoskoskiRJr. (2014). The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res, 79:34–74.
25.
Appert-CollinA, HubertP, CremelG and BennasrouneA. (2015). Role of ErbB Receptors in Cancer Cell Migration and Invasion. Front Pharmacol, 6:283.
26.
OwenBM, MangelsdorfDJ and KliewerSA. (2015). Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol Metab, 26:22–29.
27.
WescheJ, HaglundK and HaugstenEM. (2011). Fibroblast growth factors and their receptors in cancer. Biochem J, 437:199–213.
28.
LeeMY, SunL and VeltmaatJM. (2013). Hedgehog and Gli signaling in embryonic mammary gland development. J Mammary Gland Biol Neoplasia, 18:133–138.
29.
AcarA, SimoesBM, ClarkeRB and BrennanK. (2016). A Role for Notch Signalling in Breast Cancer and Endocrine Resistance. Stem Cells Int 2016, 2498764.
30.
MassagueJ. (2008). TGFbeta in Cancer. Cell, 134:215–230.
31.
NusseR.: the Wnt Homepage. http://web.stanford.edu/group/nusselab/cgi-bin/wnt/
32.
KenneyNJ, HuangRP, JohnsonGR, WuKX, OkamuraD, MathenyW, KordonE, GullickWJ, PlowmanG, et al. (1995). Detection and location of amphiregulin and Cripto-1 expression in the developing postnatal mouse mammary gland. Mol Reprod Dev, 41:277–286.
33.
LeJeuneS, LeekR, HorakE, PlowmanG, GreenallM and HarrisAL. (1993). Amphiregulin, epidermal growth factor receptor, and estrogen receptor expression in human primary breast cancer. Cancer Res, 53:3597–3602.
34.
LocopoN, FanelliM and GaspariniG. (1998). Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat, 52:159–173.
35.
Luengo-GilG, Gonzalez-BillalabeitiaE, Chaves-BenitoA, Garcia MartinezE, Garcia GarreE, VicenteV and Ayala de la PenaF. (2015). Effects of conventional neoadjuvant chemotherapy for breast cancer on tumor angiogenesis. Breast Cancer Res Treat, 151:577–587.
36.
Murphy-UllrichJE and PoczatekM. (2000). Activation of latent TGF-beta by thrombospondin-1: mechanisms and physiology. Cytokine Growth Factor Rev, 11:59–69.
37.
KonecnyGE, PegramMD, VenkatesanN, FinnR, YangG, RahmehM, UntchM, RusnakDW, SpeharG, et al. (2006). Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells. Cancer Res, 66:1630–1639.
38.
LyuH, HuangJ, EdgertonSM, ThorAD, HeZ and LiuB. (2015). Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells. Int J Clin Exp Pathol, 8:6143–6156.
39.
HolbroT, BeerliRR, MaurerF, KoziczakM, BarbasCF3rd and HynesNE. (2003). The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Natl Acad Sci U S A, 100:8933–8938.
40.
FarooquiM, BohrerLR, BradyNJ, ChuntovaP, KempSE, WardwellCT, NelsonAC and SchwertfegerKL. (2015). Epiregulin contributes to breast tumorigenesis through regulating matrix metalloproteinase 1 and promoting cell survival. Mol Cancer, 14:138.
41.
ZhouZN, SharmaVP, BeatyBT, Roh-JohnsonM, PetersonEA, Van RooijenN, KennyPA, WileyHS, CondeelisJS and SegallJE. (2014). Autocrine HBEGF expression promotes breast cancer intravasation, metastasis and macrophage-independent invasion in vivo. Oncogene, 33:3784–3793.
42.
WansburyO, PanchalH, JamesM, ParryS, AshworthA and HowardB. (2008). Dynamic expression of Erbb pathway members during early mammary gland morphogenesis. J Invest Dermatol, 128:1009–1021.
43.
KishimotoT. (2005). Interleukin-6: from basic science to medicine—40 years in immunology. Annu Rev Immunol, 23:1–21.
44.
KnupferH and PreissR. (2007). Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat, 102:129–135.
45.
MoranchoB, Zacarias-FluckM, EsguevaA, Di CosimoS, PratA, CortesJ, ArribasJ and RubioIT. (2016). Modeling anti-IL-6 therapy using breast cancer patient-derived xenografts. Oncotarget, 7:67956–67965.
46.
ShanS, LvQ, ZhaoY, LiuC, SunY, XiK, XiaoJ and LiC. (2015). Wnt/beta-catenin pathway is required for epithelial to mesenchymal transition in CXCL12 over expressed breast cancer cells. Int J Clin Exp Pathol, 8:12357–12367.
47.
FangZQ, ZangWD, ChenR, YeBW, WangXW, YiSH, ChenW, HeF and YeG. (2013). Gene expression profile and enrichment pathways in different stages of bladder cancer. Genet Mol Res, 12:1479–1489.
BegheB, HallIP, ParkerSG, MoffattMF, WardlawA, ConnollyMJ, FabbriLM, RuseC and SayersI. (2010). Polymorphisms in IL13 pathway genes in asthma and chronic obstructive pulmonary disease. Allergy, 65:474–481.
50.
BrownWS, TanL, SmithA, GrayNS and WendtMK. (2016). Covalent targeting of fibroblast growth factor receptor inhibits metastatic breast cancer. Mol Cancer Ther, 15:2096–2106.
51.
ShiYJ, TsangJY, NiYB, ChanSK, ChanKF and TseGM. (2016). FGFR1 is an adverse outcome indicator for luminal A breast cancers. Oncotarget, 7:5063–5073.
52.
HierroC, RodonJ and TaberneroJ. (2015). Fibroblast growth factor (FGF) receptor/FGF inhibitors: novel targets and strategies for optimization of response of solid tumors. Semin Oncol, 42:801–819.
53.
TurnerN and GroseR. (2010). Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer, 10:116–129.
54.
Ruiz i AltabaA. (1999). Gli proteins and Hedgehog signaling: development and cancer. Trends Genet, 15:418–425.
55.
RimkusTK, CarpenterRL, QasemS, ChanM and LoHW. (2016). Targeting the sonic hedgehog signaling pathway: review of smoothened and GLI inhibitors. Cancers (Basel), 8:22.
56.
HuiM, CazetA, NairR, WatkinsDN, O'TooleSA and SwarbrickA. (2013). The Hedgehog signalling pathway in breast development, carcinogenesis and cancer therapy. Breast Cancer Res, 15:203.
57.
ParkJP, RaafatA, FeltraccoJA, BlandingWM and BoothBW. (2013). Differential gene expression in nuclear label-retaining cells in the developing mouse mammary gland. Stem Cells Dev, 22:1297–1306.
58.
BourasT, PalB, VaillantF, HarburgG, Asselin-LabatML, OakesSR, LindemanGJ and VisvaderJE. (2008). Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell, 3:429–441.
59.
WuWR, ZhangR, ShiXD, YiC, XuBL, and LiuC. (2016). Notch2 is a crucial regulator of self-renewal and tumorigenicity in human hepatocellular carcinoma cells. Oncol Rep, 36:181–188.
60.
DicksonBC, MulliganAM, ZhangH, LockwoodG, O'MalleyFP, EganSE, and ReedijkM. (2007). High-level JAG1 mRNA and protein predict poor outcome in breast cancer. Mod Pathol, 20:685–693.
61.
CarreiraAC, AlvesGG, ZambuzziWF, SogayarMC and GranjeiroJM. (2014). Bone Morphogenetic Proteins: structure, biological function and therapeutic applications. Arch Biochem Biophys, 561:64–73.
62.
BoulangerCA, WagnerKU and SmithGH. (2005). Parity-induced mouse mammary epithelial cells are pluripotent, self-renewing and sensitive to TGF-beta1 expression. Oncogene, 24:552–560.
63.
MatulkaLA, TriplettAA and WagnerKU. (2007). Parity-induced mammary epithelial cells are multipotent and express cell surface markers associated with stem cells. Dev Biol, 303:29–44.
64.
WagnerKU, BoothBW, BoulangerCA and SmithGH. (2013). Multipotent PI-MECs are the true targets of MMTV-neu tumorigenesis. Oncogene, 32:1338.
MilovanovicT, PlanutisK, NguyenA, MarshJL, LinF, HopeC and HolcombeRF. (2004). Expression of Wnt genes and frizzled 1 and 2 receptors in normal breast epithelium and infiltrating breast carcinoma. Int J Oncol, 25:1337–1342.
67.
VouyovitchCM, PerryJK, LiuDX, BezinL, VilainE, DiazJJ, LobiePE and MertaniHC. (2016). WNT4 mediates the autocrine effects of growth hormone in mammary carcinoma cells. Endocr Relat Cancer, 23:571–585.
68.
YangL, WuX, WangY, ZhangK, WuJ, YuanYC, DengX, ChenL, KimCC, et al. (2011). FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene, 30:4437–4446.
69.
SaitohT, MineT and KatohM. (2002). Up-regulation of Frizzled-10 (FZD10) by beta-estradiol in MCF-7 cells and by retinoic acid in NT2 cells. Int J Oncol, 20:117–120.
70.
AblaO and RibeiroRC. (2013). How I treat children and adolescents with acute promyelocytic leukaemia. Br J Haematol, 164:24–38.
71.
LeszczynieckaM, RobertsT, DentP, GrantS and FisherPB. (2001). Differentiation therapy of human cancer: basic science and clinical applications. Pharmacol Ther, 90:105–156.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
